Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / John Hsu
Person

John Hsu

Tracked across 2 events · 12 articles · First seen Apr 13, 2026 · Last active Aug 24, 2026

Sentiment
30
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
2 10
Business
Anbogen and University of Tokyo Collaborate on ABT-301
AnBogen Therapeutics Inc. (TPEx: 7784), a Taiwan-based clinical-stage precision oncology company, announced on August 24, 2026 that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of…
Impact: As Chairman and CEO of Anbogen, John Hsu is a key driver of the collaboration, emphasizing its strategic importance for the company's clinical development.
Jul 20, 2026 · 6 articles
4 50
Tech
AnBogen Imofinostat Cancer Breakthroughs
Impact: John Hsu, CEO of AnBogen Therapeutics, commented on the international academic recognition of Imofinostat's innovative mechanism and the company's plans for accelerating clinical trials and an Emerging Stock Market listing.
Apr 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Track John Hsu live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.